Wyeth and Zealand Pharma Advance the First Orally Available Gap Junction Modifier into Phase I Clinical Trials

Zealand Pharma A/S (Zealand) today announced that it received a milestone payment from Wyeth (NYSE: WYE) due to Zealand for the advancement of the first orally available gap junction modifier ZP1609 (GAP-134) into phase I clinical trials in the US.